Collier, Ann C, MD

Faculty

Collier, Ann C, MD
Professor of Medicine
Director, UW AIDS Clinical Trials Unit

CONTACT INFORMATION
Box 359929
Harborview Medical Center
325 Ninth Avenue
Seattle, WA 98104
Phone: (206) 731-3293
Fax: (206) 731-3483
acollier@u.washington.edu

LINK TO ANN COLLIER'S COMMUNITY OF SCIENCE WEB PAGE

CURRENT RESEARCH INTERESTS

Dr. Collier's program focuses on clinical investigation of multiple aspects of human immunodeficiency virus (HIV) and AIDS. Ongoing clinical research projects focus primarily on antiretroviral treatment of HIV-1 and its associated complications. Collaborative projects include studies with Drs. James Mullins and Lawrence Corey about primary HIV-1, with Dr. Christina Marra about central nervous system HIV-1, with Dr. Robert Coombs about genital tract HIV-1, and with Dr. Mari Kitahata about health outcomes with antiretroviral therapy. Multiple antiretroviral therapies are under investigation; ongoing treatment trials are both single- and multi-center in nature, the latter studies are through the NIAID-sponsored AIDS Clinical Trials Group or private sponsors. The current subjects under study include the full spectrum of HIV infection (asymptomatic to AIDS). Skills to be learned include clinical research study design, protocol development, study implementation and conduct, and data analyses. Close collaboration exists between the clinic and immunology, retrovirology, and pharmacology research laboratories.

PUBLICATIONS

Collier AC, Kalish LA, Busch MP, Gernsheimer T, Assmann SF, Lane TA, Asmuth DM, Lederman MM, Murphy EL, Kumar P, Kelley M, Flanigan TP, McMahon DK, Sacks HS, Kennedy MS, Holland PV for the Viral Activation Transfusion Study Group. Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection. JAMA 285:1592-1601, 2001.

Berrey MM, Schacker T, Collier AC, Shea T, Brodie SJ, Mayers D, Coombs R, Krieger J, Chun T-W, Fauci A, Self SG, Corey L. Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis 183:1466-75, 2001.

Para MF, Glidden DV, Coombs RW, Collier AC, Condra JH, Craig C, Bassett R, Leavitt R, Snyder S, McAuliffe V, Boucher C for the AIDS Clinical Trials Group Protocol 333 team. Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS Clincal Trials Group Protocol 333. J Infect Dis 183:1466-75, 2001.